Release date: 17 December 2007
Promoter – Financial Intermediary
Sanofi-Aventis
Location
Description
The project concerns the design, construction or modernisation, and the equipment of several buildings providing facilities for pharmacological research, product development facilities and office space in Europe.
Objectives
The project aims at regrouping and reorganizing the promoter’s R&D activities in order to optimize the use of premises and equipments and facilitate the synergies between different therapeutic areas. It concerns the design, construction or modernisation, and the equipment of several buildings providing facilities for pharmacological research and office space in Europe. The facilities will be located in France, Germany, United Kingdom, Spain and Italy, mostly in the promoter’s existing R&D sites.
Sector(s)
Proposed EIB finance (Approximate amount)
EUR 350 million.
Total cost (Approximate amount)
EUR 999 million.
Environmental aspects
The sub-projects fall under Annex II of the directive EU/97/11 amended by Directive 2003/35/EC on Environmental Impact Assessment (EIA). The determination made by the competent authorities for requesting (or not) an EIA on the basis of Annex III of the Directive and actual/possible significant impacts on protected flora and fauna (Habitats’ and Birds’ Directives) has been verified during project appraisal.
Procurement
The promoter is a private company not operating in the Utilities sector, and is thus not covered by EU Directives on procurement. Procedures followed have been verified during appraisal.
Status
Signed - 13/12/2007
Disclaimer
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).